CFTR-dependent susceptibility of the cystic fibrosis-host to Pseudomonas aeruginosa

International Journal of Medical Microbiology

Volumn 300, Issue 8, 2010, Pages 578-583

  Grassmé, Heike ^a   Becker, Katrin Anne ^a   Zhang, Yang ^a   Gulbins, Erich ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Ceramide; Cftr; Cystic fibrosis; P. aeruginosa

Indexed keywords

CAVEOLIN; CERAMIDE; DEATH RECEPTOR; FAS ANTIGEN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

BURKHOLDERIA CEPACIA; CELL PH; CHRONIC INFLAMMATION; CYSTIC FIBROSIS; EPITHELIUM CELL; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION SENSITIVITY; LIPID METABOLISM; LIPID RAFT; LUNG FIBROSIS; MUCOCILIARY CLEARANCE; NONHUMAN; NOSE MUCOSA; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SHORT SURVEY; STAPHYLOCOCCUS AUREUS;

ANIMALS; BURKHOLDERIA CEPACIA; CERAMIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HAEMOPHILUS INFLUENZAE; HUMANS; MODELS, ANIMAL; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 78549249994     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2010.08.011     Document Type: Short Survey

References (52)

1. Bajmoczi M., Gadjeva M., Alper S.L., Pier G.B., Golan D.E. Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. Am. J. Physiol. Cell Physiol. 2009, 297:C263-C277.
2. Barasch J., Kiss B., Prince A., Saiman L., Gruenert D., al-Awqati Q. Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991, 352:70-73.
3. Becker K.A., Riethmüller J., Lüth A., Döring G., Kleuser B., Gulbins E. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am. J. Resp. Cell Mol. Biol. 2010, 42:716-724.
4. Bonfield T.L., Konstan M.W., Burfeind P., Panuska J.R., Hilliard J.B., Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 1995, 13:257-261.
5. Boucher R.C. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu. Rev. Med. 2007, 58:157-170.
6. Brown D.A., London E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell Dev. Biol. 1998, 14:111-136.
7. Charizopoulou N., Jansen S., Dorsch M., Stanke F., Dorin J.R., Hedrich H.-J., Tümmler B. Instability of the insertional mutation in CftrTgH(neoim)Hgu cystic fibrosis mouse model. BMC Genetics 2004, 5:6.
8. Charizopoulou N., Wilke M., Dorsch M., Bot A., Jorna H., Jansen S., Stanke F., Hedrich H.-J., de Jonge H.R., Tümmler B. Spontaneous rescue from cystic fibrosis in a mouse model. BMC Genetics 2006, 7:18.
9. Coleman F.T., Mueschenborn S., Meluleni G., Ray C., Carey V.J., Vargas S.O., Cannon C.L., Ausubel F.M., Pier G.B. Hypersuceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc. Natl. Acad Sci. USA 2003, 100:1949-1954.
10. Colledge W.H., Abella B.S., Southern K.W., Ratcliff R., Jiang C., Cheng S.H., MacVinish L.J., Anderson J.R., Cuthbert A.W., Evans M.J. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat. Genet. 1995, 10:445-452.
11. Delaney S.J., Alton E.W., Smith S.N., Lunn D.P., Farley R., Lovelock P.K., Thomson S.A., Hume D.A., Lamb D., Porteous D.J., Dorin J.R., Wainwright B.J. Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO J. 1996, 15:955-963.
12. Di A., Brown M.E., Deriy L.V., Li C., Szeto F.L., Chen Y., Huang P., Tong J., Naren A.P., Bindokas V., Palfrey H.C., Nelson D.J. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 2006, 8:933-944.
13. Dickinson P., Smith S.N., Webb S., Kilanowski F.M., Campbell I.J., Taylor M.S., Porteous D.J., Willemsen R., de Jonge H.R., Farley R., Alton E.W., Dorin J.R. The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mistrafficking, normal survival and organ-specific bioelectrics. Hum. Mol. Genet. 2002, 11. pp. 243-225.
14. Dorin J.R., Dickinson P., Emslie E., Clarke A.R., Dobbie L., Hooper M.L., Halford S., Wainwright B.J., Porteous D.J. Successful targeting of the mouse cystic fibrosis transmembrane conductance regulator gene in embryonal stem cells. Transgenic Res. 1992, 1:101-105.
15. Durie P.R., Kent G., Phillips M.J., Ackerley C.A. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am. J. Pathol. 2004, 164:1481-1493.
16. Eggeling C., Ringemann C., Medda R., Schwarzmann G., Sandhoff K., Polyakova S., Belov V.N., Hein B., von Middendorff C., Schönle A., Hell S.W. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 2009, 457:1159-1162.
17. Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., Henson P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2 and PAF. J. Clin. Invest. 1998, 101:890-898.
18. Gadjeva M., Paradis-Bleau C., Priebe G.P., Fichorova R., Pier G.B. Caveolin-1 modifies the immunity to Pseudomonas aeruginosa. J. Immunol. 2010, 184:296-302.
19. Grassmé H., Jendrossek V., Riehle A., von Kürthy G., Berger J., Schwarz H., Weller M., Kolesnick R., Gulbins E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 2003, 9:322-330.
20. Grassmé H., Kirschnek S., Riethmueller J., Riehle A., von Kürthy G., Lang F., Weller M., Gulbins E. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000, 290:527-530.
21. Gray M.A., Winpenny J.P., Porteous D.J., Dorin J.R., Argent B.E. CFTR and calcium-activated chloride currents in pancreatic duct cells of a transgenic CF mouse. Am. J. Physiol. 1994, 266:C213-C221.
22. Guilbault C., De Sanctis J.B., Wojewodka G., Saeed Z., Lachance C., Skinner T.A., Vilela R.M., Kubow S., Lands L.C., Hajduch M., Matouk E., Radzioch D. Fenetinide corrects newly found ceramide deficiency in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 2008, 38:47-56.
23. Gulbins E., Kolesnick R.N. Raft ceramide in molecular medicine. Oncogene 2003, 22:7070-7077.
24. Haggie P.M., Verkman A.S. Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J. Biol. Chem. 2007, 282:31422-31428.
25. Hodges C.A., Cotton C.U., Palmert M.R., Drumm M.L. Generation of a conditional null allele for Cftr in mice. Genesis 2008, 46:546-552.
26. Hoffmann N., Bovbjerg Rasmussen T., Ostrup Jensen P., Stub C., Hentzer M., Molin S., Ciofu O., Givskov M., Krogh Johansen H., Høiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect. Immun. 2005, 73:2504-2514.
27. Hurwitz R., Ferlinz K., Sandhoff K. The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol. Chem. Hoppe Seyler 1994, 375:447-450.
28. Inoue H., Massion P.P., Ueki I.F., Grattan K.M., Hara M., Dohrman A.F., Chan B., Lausier J.A., Golden J.A., Nadel J.A. Pseudomonas stimulates interleukin-8 mRNA expression selectively in airway epithelium, in gland ducts, and in recruited neutrophils. Am. J. Respir. Cell Mol. Biol. 1994, 11:651-663.
29. Kent G., Iles R., Bear C.E., Huan L.J., Griesenbach U., McKerlie C., Frndova H., Ackerley C., Gosselin D., Radzioch D., OóBrodovich H., Tsui L.C., Buchwald M., Transwell A.K. Lung disease in mice with cystic fibrosis. J. Clin. Invest. 1997, 100:3060-3069.
30. Kent G., Oliver M., Foskett J.K., Frndova H., Durie P., Forstner J., Forstner G.G., Riordan J.R., Percy D., Buchwald M. Phenotypic abnormalities in long-term surviving cystic fibrosis mice. Pediatr. Res. 1996, 40:233-241.
31. Kerem B., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., Buchwald M., Tsui L.C. Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
32. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1995, 151:1075-1082.
33. Kolesnick R.N., Goni F.M., Alonso A. Compartmentalization of ceramide signaling: physical foundations and biological effects. J. Cell. Physiol. 2000, 184:285-300.
34. Kowalski M.P., Pier G.B. Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation. J. Immunol. 2004, 172:418-425.
35. Kumar V., Becker T., Jansen S., van Barneveld A., Boztug K., Wolfl S., Tümmler B., Stanke F. Expression levels of FAS are regulated through an evolutionary conserved element in intron 2, which modulates cystic fibrosis disease severity. Genes Immun. 2008, 9:689-696.
36. tm1Hgu cystic fibrosis mice: impact on morphology and physiology. Pathobiology 2002, 70:89-97.
37. Matsui H., Grubb B.R., Tarran R., Randell S.H., Gatzy J.T., Davis C.W., Boucher R.C. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005-1015.
38. Ratcliff R., Evans M.J., Cuthbert A.W., MacVinish L.J., Foster D., Anderson J.R., Colledge W.H. Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat. Genet. 1993, 4:35-41.
39. Riethmüller J., Anthonysamy J., Emilio Serra E., Schwab M., Döring G., Gulbins E. Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell. Physiol. Biochem. 2009, 22:405-412.
40. Rommens J.M., Iannuzzi M.C., Kerem B., Drumm M.L., Melmer G., Dean M., Rozmahel R., Cole J.L., Kennedy D., Hidaka N., Zsiga M., Buchwald M., Riordan J.R., Tsui L.-C., Collins F.S. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
41. Sekine C., Yagita H., Kobata T., Hasunuma T., Nishioka K., Okumura K. Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis. Biochem. Biophys. Res. Commun. 1996, 228:14-20.
42. Signorelli P., Munoz-Olaya J.M., Gagliostro V., Casas J., Ghidoni R., Fabriàs G. Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Lett. 2009, 282:238-243.
43. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
44. Snouwaert J.N., Brigman K.K., Latour A.M., Malouf N.N., Boucher R.C., Smithies O., Koller B.H. An animal model for cystic fibrosis made by gene targeting. Science 1992, 257:1083-1088.
45. Tabary O., Escotte S., Couetil J.P., Hubert D., Dusser D., Puchelle E., Jacquot J. Relationship between IkappaBalpha deficiency. NFkappaB activity and interleukin-8 production in CF human airway epithelial cells. Pflugers Arch. 2001, 443(Suppl. 1):S40-S44.
46. Teichgräber V., Ulrich M., Endlich N., Riethmüller J., Wilker B., De Oliveira-Munding C.C., van Heeckeren A.M., Barr M.L., von Kürthy G., Schmid K.W., Weller M., Tümmler B., Lang F., Grassmé H., Döring G., Gulbins E. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 2008, 14:382-391.
47. Venkatakrishnan A., Stecenko A.A., King G., Blackwell T.R., Brigham K.L., Christman J.W., Blackwell T.S. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol. 2000, 23:396-403.
48. Verhaeghe C., Delbecque K., de Leval L., Oury C., Bours V. Early inflammation in the airways of a cystic fibrosis foetus. J. Cyst. Fibros. 2007, 6:304-308.
49. Yu H., Zeidan Y.H., Wu B.X., Jenkins R.W., Flotte T.R., Hannun Y.A., Virella-Lowell I. Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 2009, 41:367-375.
50. Zaas D.W., Duncan M.J., Li G., Wright J.R., Abramson S.N. Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2. J. Biol. Chem. 2005, 280:4864-4872.
51. Zeiher B.G., Eichwald E., Zabner J., Smith J.J., Puga A.P., McCray P.B., Capecchi M.R., Welsh M.J., Thomas K.R. A mouse model for the delta F508 allele of cystic fibrosis. J. Clin. Invest. 1995, 96:2051-2064.
52. Zhang Y., Li X., Grassmé H., Döring G., Gulbins E. Alterations in ceramide concentration and pH determine the release of reactive oxygen species by Cftr-deficient macrophages upon infection. J. Immunol. 2010, 184:5104-5111.